Cargando…

Interpretation of breast cancer screening guideline for Chinese women

Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yubei, Tong, Zhongsheng, Chen, Kexin, Wang, Ying, Liu, Peifang, Gu, Lin, Liu, Juntian, Yu, Jinpu, Song, Fengju, Zhao, Wenhua, Shi, Yehui, Li, Hui, Xiao, Huaiyuan, Hao, Xishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936244/
https://www.ncbi.nlm.nih.gov/pubmed/31908899
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322
_version_ 1783483707208761344
author Huang, Yubei
Tong, Zhongsheng
Chen, Kexin
Wang, Ying
Liu, Peifang
Gu, Lin
Liu, Juntian
Yu, Jinpu
Song, Fengju
Zhao, Wenhua
Shi, Yehui
Li, Hui
Xiao, Huaiyuan
Hao, Xishan
author_facet Huang, Yubei
Tong, Zhongsheng
Chen, Kexin
Wang, Ying
Liu, Peifang
Gu, Lin
Liu, Juntian
Yu, Jinpu
Song, Fengju
Zhao, Wenhua
Shi, Yehui
Li, Hui
Xiao, Huaiyuan
Hao, Xishan
author_sort Huang, Yubei
collection PubMed
description Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China.
format Online
Article
Text
id pubmed-6936244
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-69362442020-01-06 Interpretation of breast cancer screening guideline for Chinese women Huang, Yubei Tong, Zhongsheng Chen, Kexin Wang, Ying Liu, Peifang Gu, Lin Liu, Juntian Yu, Jinpu Song, Fengju Zhao, Wenhua Shi, Yehui Li, Hui Xiao, Huaiyuan Hao, Xishan Cancer Biol Med Guideline Interpretation Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China. Chinese Anti-Cancer Association 2019-11 /pmc/articles/PMC6936244/ /pubmed/31908899 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322 Text en Copyright 2019 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Guideline Interpretation
Huang, Yubei
Tong, Zhongsheng
Chen, Kexin
Wang, Ying
Liu, Peifang
Gu, Lin
Liu, Juntian
Yu, Jinpu
Song, Fengju
Zhao, Wenhua
Shi, Yehui
Li, Hui
Xiao, Huaiyuan
Hao, Xishan
Interpretation of breast cancer screening guideline for Chinese women
title Interpretation of breast cancer screening guideline for Chinese women
title_full Interpretation of breast cancer screening guideline for Chinese women
title_fullStr Interpretation of breast cancer screening guideline for Chinese women
title_full_unstemmed Interpretation of breast cancer screening guideline for Chinese women
title_short Interpretation of breast cancer screening guideline for Chinese women
title_sort interpretation of breast cancer screening guideline for chinese women
topic Guideline Interpretation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936244/
https://www.ncbi.nlm.nih.gov/pubmed/31908899
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322
work_keys_str_mv AT huangyubei interpretationofbreastcancerscreeningguidelineforchinesewomen
AT tongzhongsheng interpretationofbreastcancerscreeningguidelineforchinesewomen
AT chenkexin interpretationofbreastcancerscreeningguidelineforchinesewomen
AT wangying interpretationofbreastcancerscreeningguidelineforchinesewomen
AT liupeifang interpretationofbreastcancerscreeningguidelineforchinesewomen
AT gulin interpretationofbreastcancerscreeningguidelineforchinesewomen
AT liujuntian interpretationofbreastcancerscreeningguidelineforchinesewomen
AT yujinpu interpretationofbreastcancerscreeningguidelineforchinesewomen
AT songfengju interpretationofbreastcancerscreeningguidelineforchinesewomen
AT zhaowenhua interpretationofbreastcancerscreeningguidelineforchinesewomen
AT shiyehui interpretationofbreastcancerscreeningguidelineforchinesewomen
AT lihui interpretationofbreastcancerscreeningguidelineforchinesewomen
AT xiaohuaiyuan interpretationofbreastcancerscreeningguidelineforchinesewomen
AT haoxishan interpretationofbreastcancerscreeningguidelineforchinesewomen